MEDS Clinical Medicine (2024)
Clausius Scientific Press, Canada

DOI: 10.23977/medsc.2024.050303
ISSN 2616-1907 Vol. 5 Num. 3

Research Progress on Omeprazole in the Treatment of Peptic Ulcers

Ouyang Zhang[1], Zhipeng Xu[2]

[1]*Department of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, 637100, China*
[2]*Department of Medical Imaging, North Sichuan Medical College, Nanchong, Sichuan, 637100, China*

Keywords: Omeprazole, peptic ulcer, proton pump inhibitor, pharmacological characteristics

Abstract: This paper provides a comprehensive review of the research progress on omeprazole in the treatment of peptic ulcers. Peptic ulcer is a common gastrointestinal disease with a complex pathogenesis and diverse clinical manifestations. Omeprazole, as a proton pump inhibitor, is widely used in the treatment of peptic ulcers by inhibiting gastric acid secretion. This paper systematically summarizes and discusses the pharmacological characteristics, clinical research progress, safety evaluation, and future development trends of omeprazole. The synthesis of various research results shows that omeprazole exhibits good efficacy and safety in the treatment of peptic ulcers, but there are still some issues that need further research and resolution. With the continuous advancement of science and technology, the future application prospects of omeprazole in the treatment of peptic ulcers will be broader.

1. Introduction

Peptic ulcer is a common and serious gastrointestinal disease, with a high incidence globally. This disease seriously affects the quality of life and health of patients, thus attracting widespread attention from the medical community. The pathogenesis of peptic ulcers involves multiple factors, including gastric mucosal damage, abnormal gastric acid secretion, and disruption of mucosal protection mechanisms. In the treatment of peptic ulcers, inhibiting gastric acid secretion is considered a key strategy. Proton pump inhibitors are one of the main drugs currently used to treat peptic ulcers. They effectively reduce gastric acid secretion by inhibiting the activity of gastric acid pumps, thereby aiding ulcer healing and symptom relief. Among proton pump inhibitors, omeprazole is a widely used drug due to its pharmacological characteristics, making it one of the preferred drugs for the treatment of peptic ulcers. However, despite the certain efficacy achieved by omeprazole in clinical practice, its long-term use may lead to some adverse reactions and side effects, emphasizing the importance of comprehensive safety assessment. This paper aims to systematically review the research progress of omeprazole in the treatment of peptic ulcers, including its pharmacological characteristics, clinical research progress, safety evaluation, and future development trends. By summarizing and synthesizing relevant research, we will

comprehensively evaluate the efficacy and safety of omeprazole in the treatment of peptic ulcers and provide prospects for future research and clinical application[1].

2. Overview of Peptic Ulcers

2.1. Definition and Classification of Peptic Ulcers

Peptic ulcers refer to localized lesions occurring in the mucosal layer of the stomach or duodenum, typically resulting from prolonged exposure to gastric acid and pepsin. These ulcers can occur in the stomach (referred to as gastric ulcers) or the duodenum (referred to as duodenal ulcers), characterized by localized damage and destruction of the mucosal layer. Based on the location and nature of the ulcers, peptic ulcers are generally classified into the following types:

1) Gastric Ulcers: Ulcers located in the gastric mucosal layer, typically occurring in the gastric antrum or lesser curvature.

2) Duodenal Ulcers: Ulcers located in the duodenal mucosal layer, typically occurring in the duodenal bulb or descending part.

3) Acute Ulcers: Ulcers with fresh bleeding, congestion, and exudation on the ulcer surface, often accompanied by acute inflammatory reactions.

4) Chronic Ulcers: Ulcers that recur and heal repeatedly, forming larger, deeper ulcer craters, accompanied by fibrous tissue proliferation and scar formation.

5) Recurrent Ulcers: Ulcers that recur frequently, with a tendency to relapse or develop new ulcers after treatment.

6) Complicated Ulcers: Ulcers accompanied by other diseases or complications, such as ulcer bleeding, perforation, or pyloric obstruction.

Different types of peptic ulcers may exhibit variations in clinical manifestations, pathogenesis, and treatment strategies, highlighting the importance of understanding their definitions and classifications for clinical diagnosis and treatment[2].

2.2. Etiology and Pathogenesis

The pathogenesis of peptic ulcers involves the interaction of various factors. Firstly, excessive secretion of gastric acid and pepsin is one of the main causes of peptic ulcer formation. Excessive secretion of gastric acid leads to erosion and damage to the gastric mucosal layer, while activation of gastric pepsin further exacerbates mucosal injury. Secondly, impairment of gastric mucosal barrier function is also an important factor in ulcer formation. Under normal circumstances, the gastric mucosal layer has a certain barrier function, which can resist the invasion of gastric acid and other harmful substances. However, factors such as nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol, and stress can disrupt this barrier, making it susceptible to injury. In addition, Helicobacter pylori infection is closely associated with the occurrence of peptic ulcers. The bacterium invades the gastric mucosa and releases toxins, causing inflammatory reactions and damaging the gastric mucosal barrier, thereby promoting ulcer formation. In addition to the above factors, genetic factors, smoking, dietary habits, and psychological stress may also influence the occurrence of peptic ulcers. These factors may participate in the pathogenesis of ulcers by affecting gastric acid secretion, mucosal barrier function, or Helicobacter pylori infection. Understanding these mechanisms is of great significance for formulating effective treatment strategies and preventive measures[3].

2.3. Clinical Manifestations

The clinical manifestations of peptic ulcers mainly include upper abdominal pain, dyspepsia, and

complications. The most common symptom is upper abdominal pain, usually located in the gastric antrum or lesser curvature, presenting as intermittent or persistent pain associated with food intake. This pain may worsen at night or on an empty stomach and may be relieved or alleviated after food intake. Dyspepsia is also a common symptom of peptic ulcers, including bloating, abdominal distension, nausea, and vomiting. In severe cases, peptic ulcers may also lead to complications such as ulcer bleeding, perforation, and pyloric obstruction. Ulcer bleeding may manifest as melena or hematemesis and is the most common complication of acute ulcers. Ulcer perforation causes severe, persistent upper abdominal pain and may lead to peritonitis or sepsis. Pyloric obstruction occurs when ulcers near the pylorus cause stenosis or obstruction, resulting in postprandial upper abdominal distension and vomiting. In summary, the clinical manifestations of peptic ulcers are diverse, requiring comprehensive consideration of patient symptoms and signs for accurate diagnosis and treatment.

3. Pharmacological Characteristics of Omeprazole

3.1. Mechanism of Action

In the pharmacotherapy of peptic ulcers, proton pump inhibitors (PPIs) are a commonly used drug class, with omeprazole being one of the representative drugs. Omeprazole inhibits gastric acid secretion by acting on the proton pump in gastric mucosal cells, thereby achieving the goal of ulcer treatment. Specifically, as a proton pump inhibitor, omeprazole binds to the H^+/K^+ ATPase (proton pump) in gastric mucosal cells, forming hydrogen bonds, thus inhibiting its activity. This process occurs in the secretory tubule system of gastric mucosal cells. The proton pump is an important protein in gastric mucosal cells, mainly responsible for transporting hydrogen ions from the cell interior to the gastric lumen, promoting the formation of gastric acid. Omeprazole binding blocks the activity of the proton pump, inhibiting gastric acid secretion[4]. This inhibitory effect lasts for a long time, over 12 hours, effectively reducing gastric acidity and promoting ulcer healing. Furthermore, omeprazole can also improve the acid-base balance in the ulcer area by reducing gastric acid secretion, thereby reducing further damage to the mucosa. In the treatment of peptic ulcers, the pharmacological mechanism of omeprazole plays a crucial role in alleviating symptoms, promoting ulcer healing, and preventing recurrence.

3.2. Pharmacokinetics

The pharmacokinetics of omeprazole refer to the processes of absorption, distribution, metabolism, and excretion of the drug in the body. Omeprazole, as a proton pump inhibitor, is mainly administered orally. Under acidic conditions, omeprazole can remain stable, but it easily decomposes in neutral or alkaline environments. Therefore, it is generally recommended to take omeprazole on an empty stomach to ensure its stability and absorption in the acidic environment of the stomach. Omeprazole is mainly absorbed in the small intestine, with a rapid absorption rate. Once absorbed, omeprazole is transported to various tissues and organs throughout the body via the bloodstream. However, it mainly concentrates in gastric mucosal cells, where it binds to the proton pump to form hydrogen bonds, thereby exerting its inhibitory effect on gastric acid secretion. In the body, omeprazole is primarily metabolized by the liver, utilizing liver enzyme systems such as CYP2C19 and CYP3A4 for metabolism. The metabolites are mainly inactive metabolites without pharmacological activity. Finally, omeprazole and its metabolites are mainly excreted in the urine, with a small amount excreted in the bile. Due to the half-life of omeprazole being approximately 1-2 hours, it is recommended to take it once or twice daily to maintain stable drug plasma concentrations. In summary, the pharmacokinetic characteristics of omeprazole make it an effective

and safe drug widely used in the treatment of peptic ulcers and other gastrointestinal diseases.

3.3. Pharmacodynamics

Pharmacodynamics is the study of the effects of drugs on biological systems. For proton pump inhibitors like omeprazole, their main pharmacodynamic effect is the inhibition of gastric acid secretion, thereby reducing the stimulation and damage of gastric acid to gastric mucosa and promoting the healing of peptic ulcers. Specifically, omeprazole binds to the H^+/K^+ ATPase (proton pump) in gastric mucosal cells, forming hydrogen bonds, and inhibiting the activity of the proton pump. This process prevents the transport of hydrogen ions from gastric mucosal cells to the gastric lumen, reducing gastric acid secretion. With the decrease in gastric acid secretion, gastric acidity decreases, which is conducive to the healing of peptic ulcers and the relief of symptoms. Moreover, omeprazole can also be used to treat peptic ulcers related to Helicobacter pylori infection. Its pharmacodynamic effect mainly involves reducing gastric acidity, creating an unfavorable environment for bacterial survival, thereby inhibiting the growth and reproduction of Helicobacter pylori and achieving the purpose of treatment. It is important to note that the therapeutic effect of omeprazole is not immediately apparent and usually requires continuous administration for several days to weeks to achieve significant efficacy. Therefore, when treating peptic ulcers, patients need to adhere to the prescribed medication regimen to ensure the full pharmacodynamic effect of the drug. At the same time, doctors need to adjust the dosage and treatment plan according to the patient's specific condition and the severity of the disease to achieve the best therapeutic effect[5].

4. Research Progress on Omeprazole in the Treatment of Peptic Ulcers

4.1. Overview of Clinical Studies

Omeprazole, as a proton pump inhibitor, has been the subject of numerous clinical studies in the treatment of peptic ulcers. These clinical studies mainly focus on the efficacy, safety, and drug application aspects of omeprazole, providing reliable evidence for its clinical use.Early clinical studies primarily compared omeprazole with traditional H2 receptor antagonists (such as ranitidine) in the treatment of peptic ulcers. These studies indicated that omeprazole had a higher healing rate, shorter healing time, longer-lasting efficacy, and fewer side effects compared to H2 receptor antagonists. With further research, the position of omeprazole in the treatment of peptic ulcers has gradually been recognized, becoming one of the preferred therapeutic agents.In recent years, with a better understanding of the relationship between Helicobacter pylori infection and peptic ulcers, research on omeprazole in the treatment of H. pylori-related ulcers has also gained increasing attention. Clinical trial results have shown that omeprazole combined with antibacterial drugs for the treatment of H. pylori infection-related peptic ulcers has good efficacy, effectively reducing ulcer recurrence and complications. Furthermore, clinical studies on omeprazole's dosage, administration regimen, and treatment duration are ongoing. These studies aim to optimize the therapeutic effects of omeprazole, reduce adverse reactions and side effects, and improve patients' quality of life. Overall, significant progress has been made in clinical research on omeprazole in the treatment of peptic ulcers, providing solid scientific support for its clinical application. With further research, it is believed that the position of omeprazole in the treatment of peptic ulcers will be further consolidated and developed.

4.2. Comparison of Omeprazole with Other Drug Therapies

Omeprazole, as a proton pump inhibitor, has been widely used in the treatment of peptic ulcers

and has been compared with other drugs in multiple studies. Comparison with H2 receptor antagonists is the most common. Several studies have shown that compared to H2 receptor antagonists, omeprazole has a higher healing rate, shorter healing time, and better prevention of recurrent ulcers. This advantage can be attributed to omeprazole's more effective inhibition of gastric acid secretion as a proton pump inhibitor, thereby reducing gastric acid's stimulation and damage to gastric mucosa, promoting ulcer healing.In addition, comparative studies have been conducted on omeprazole combined with antibiotics for the treatment of H. pylori-related ulcers. The results have shown that the omeprazole combined with antibiotic regimen has a higher cure rate and lower recurrence rate compared to omeprazole monotherapy or antibiotic therapy alone, significantly improving efficacy. This further confirms the importance of omeprazole in the treatment of H. pylori-related ulcers and the effectiveness of omeprazole combined with antibiotic therapy.Furthermore, omeprazole has also been compared with other proton pump inhibitors. Although different proton pump inhibitors have similar efficacy in the treatment of peptic ulcers, individual differences and resistance issues may exist. Therefore, when choosing a treatment regimen, it is necessary to consider the patient's condition and individual characteristics to achieve the best therapeutic effect.In summary, omeprazole has significant advantages compared to other drugs in the treatment of peptic ulcers, but the choice of specific treatment regimens still needs to consider the patient's condition and individual characteristics. With further research, it is believed that there will be a deeper understanding and guidance on the comparison between omeprazole and other drug therapies.

4.3. Evaluation of Treatment Effects

Evaluating the efficacy of omeprazole in the treatment of peptic ulcers requires consideration of multiple aspects, including healing rate, symptom relief, and reduction of complications.Firstly, the healing rate is an important indicator for evaluating treatment efficacy. Clinical studies have shown that the healing rate of peptic ulcers with omeprazole treatment is generally high, often exceeding 80%. This means that most patients can achieve ulcer healing within a certain period after receiving omeprazole treatment, thereby alleviating symptoms and improving their quality of life[6].Secondly, symptom relief is also an important indicator of treatment efficacy. Common symptoms of peptic ulcers include upper abdominal pain, dyspepsia, etc., and omeprazole can effectively relieve these symptoms, improving patients' quality of life. Clinical studies have shown that after omeprazole treatment, patients experience significant symptom relief, with most patients achieving good symptom control. Furthermore, the reduction of complications is also essential in the treatment of peptic ulcers. Omeprazole can effectively reduce gastric acid secretion, thereby reducing gastric acid's stimulation and damage to gastric mucosa, leading to a decrease in complications such as ulcer bleeding and perforation. Clinical studies have shown that omeprazole treatment can significantly reduce the incidence of complications, improving the treatment success rate and quality of life for patients. In summary, the evaluation of omeprazole's efficacy in treating peptic ulcers mainly includes indicators such as healing rate, symptom relief, and reduction of complications. Clinical studies have shown that omeprazole treatment for peptic ulcers has good efficacy and safety, making it an effective treatment drug. However, in practical application, it is necessary to develop individualized treatment plans based on the patient's specific condition and the severity of the disease to achieve the best treatment effect.

5. Safety Assessment of Omeprazole in the Treatment of Peptic Ulcers

5.1. Adverse Reactions and Side Effects

Despite the significant efficacy of omeprazole in the treatment of peptic ulcers, there are still some adverse reactions and side effects to be aware of during long-term use.Common adverse reactions include headache, nausea, diarrhea, and abdominal discomfort, among other digestive system symptoms. These adverse reactions are usually mild and quickly disappear after discontinuation, typically requiring no special treatment. However, in some individuals, severe adverse reactions may occur, such as allergic reactions, rash, abnormal liver function, etc., which require prompt medical attention. Furthermore, long-term use of omeprazole may also lead to some side effects related to nutritional absorption disorders, such as poor absorption of vitamin B12, magnesium, and other trace elements. This may increase the risk of conditions like anemia, osteoporosis, etc. Therefore, in patients on long-term omeprazole therapy, relevant nutritional monitoring is recommended, with timely supplementation of deficient nutrients as needed. Additionally, there have been reports linking long-term use of proton pump inhibitors to certain serious complications such as gastrointestinal infections, fractures, renal impairment, etc. The occurrence of these complications may be related to the potential impact of proton pump inhibitors on physiological functions and the immune system, although the specific mechanisms are not yet clear. In summary, despite the significant efficacy of omeprazole in treating peptic ulcers, close attention to its adverse reactions and side effects is necessary during long-term use. Physicians should thoroughly assess the patient's condition and medical history before prescribing, avoiding unnecessary medication, and regularly monitor the patient's condition and adverse reactions, adjusting the treatment plan as needed to ensure patient safety and efficacy.

5.2. Safety and Long-Term Use

Omeprazole, as a proton pump inhibitor, has good short-term efficacy in treating peptic ulcers, but caution is needed regarding its safety during long-term use. Long-term use of omeprazole may increase the risk of some adverse events, with the most prominent being issues related to bone health. Studies have shown an increased risk of fractures, particularly in the hip, spine, and wrist, associated with long-term use of proton pump inhibitors. This may be related to their effects on calcium absorption and the occurrence of osteoporosis. Therefore, in patients on long-term omeprazole therapy, especially in the elderly and those at risk of osteoporosis, close monitoring of bone density and preventive measures against fractures are recommended. Moreover, long-term use of omeprazole may also be associated with vitamin B12 deficiency. Proton pump inhibitors may reduce gastric acid secretion, thereby affecting the absorption of vitamin B12. Therefore, patients on long-term omeprazole therapy should undergo regular checks of vitamin B12 levels and supplement vitamin B12 when necessary. Additionally, long-term use of omeprazole may also be associated with adverse events such as renal impairment, gastrointestinal infections, and immune system suppression. Therefore, when deciding on long-term use of omeprazole in patients, the treatment efficacy needs to be balanced against the risk of adverse events, and individualized treatment plans should be developed based on the patient's specific circumstances. In conclusion, omeprazole has good efficacy in treating peptic ulcers, but caution is required regarding its safety during long-term use. Physicians should weigh the treatment efficacy against the risk of adverse events when deciding on long-term use of omeprazole, closely monitor the patient's condition and adverse reactions, to ensure patient safety and efficacy[7].

6. Future Trends in Omeprazole Treatment for Peptic Ulcers

6.1. New Research Directions and Prospects

Omeprazole, as a proton pump inhibitor, has achieved significant success in treating peptic ulcers. However, with the continuous development of medical science and changing patient needs, its future trends will mainly focus on personalized treatment plans, innovative drug designs, Helicobacter pylori treatment strategies, comprehensive treatment approaches, and innovative treatment monitoring technologies. Firstly, personalized treatment plans will be a key focus of future research. By testing aspects like patient genetics and pharmacokinetics, tailored treatment plans can be designed to maximize efficacy and minimize adverse reactions. Secondly, innovative drug design will be another future development direction. Researchers will strive to develop safer and more effective proton pump inhibitors or other novel drugs to address the potential side effects and resistance issues associated with long-term omeprazole use. Moreover, research on Helicobacter pylori infection-related peptic ulcers will focus on developing more effective treatment strategies, such as novel Helicobacter pylori inhibitors or vaccines, to improve eradication rates and reduce recurrence and complications. Additionally, future research will emphasize the integration of treatment strategies, aiming to enhance treatment efficacy comprehensively through the combined use of drugs and lifestyle interventions. Lastly, innovation in treatment monitoring technology will be an important direction for future research, including the application of imaging examinations, biomarker monitoring, and more precise methods for evaluating treatment efficacy, providing more reliable evidence for clinical decision-making. In summary, the future development of omeprazole in treating peptic ulcers will focus more on personalized treatment, innovative drug design, comprehensive treatment strategies, and the application of treatment monitoring technology to maximize efficacy and minimize side effects, thus providing patients with safer and more effective treatment options[8].

6.2. Clinical Application Prospects

With the continuous advancement of medical technology and increasing patient demands, omeprazole has broad prospects in the clinical treatment of peptic ulcers. In the future, the clinical application of omeprazole will present the following prospects: Firstly, personalized treatment will become the main trend in the future. With the development of individual genomics and pharmacokinetics, doctors will be able to more accurately predict patients' responses to omeprazole and formulate personalized treatment plans, effectively improving treatment efficacy and reducing adverse reactions. Secondly, omeprazole will play a more important role in the treatment of Helicobacter pylori-related ulcers. With a deeper understanding of the mechanism of Helicobacter pylori infection, omeprazole combined with antibiotic treatment regimens will become more precise and effective, aiming to eradicate Helicobacter pylori and effectively reduce recurrence and complication rates of ulcers. Moreover, omeprazole has broad prospects in the prevention of peptic ulcers. For patients who need long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), omeprazole can be used as a gastric mucosal protective agent to effectively prevent NSAID-related ulcers. In the future, with a deeper understanding of the pathogenesis of NSAID-related ulcers, the preventive effect of omeprazole will be more comprehensively applied.Lastly, with the continuous innovation and development of medical technology, omeprazole treatment plans will become more diverse and personalized. Combining techniques such as imaging and biomarker monitoring, doctors will be able to better assess the patient's condition and treatment efficacy, adjust treatment plans in a timely manner, and achieve precise management of patients.In conclusion, as an important drug for the treatment of peptic ulcers, omeprazole has broad prospects for clinical

application. In the future, personalized treatment, treatment of Helicobacter pylori-related ulcers, ulcer prevention, and diversified treatment plans will be the key development directions for omeprazole's clinical application.

7. Conclusion

In the field of peptic ulcer treatment, omeprazole, as a proton pump inhibitor, has demonstrated significant efficacy and safety in clinical practice. By inhibiting gastric acid secretion, omeprazole effectively promotes ulcer healing, alleviates symptoms, and reduces the occurrence of complications, providing patients with an effective treatment option. However, with the continuous advancement of medical technology and the increasing demands of patients, the future development of omeprazole remains full of challenges and opportunities. Personalized treatment, innovative drug design, Helicobacter pylori treatment strategies, comprehensive treatment approaches, and innovative treatment monitoring technologies will contribute to the maximization of treatment efficacy and the minimization of side effects. We look forward to future research continually refining omeprazole treatment plans, providing patients with safer and more effective treatment options, and bringing greater progress to the management and treatment of peptic ulcers.

References

[1] Yu. S S, O. D K, M. L K, et al. Kinetics of Omeprazole Release from Enteric Dosage Forms of Different Manufacturers [J]. Pharmaceutical Chemistry Journal, 2024, 57(10):1647-1654.

[2] Nascimento S C L A, Martins B C I, Spósito L, et al. Indomethacin-omeprazole as therapeutic hybrids? Salt and co-amorphous systems enhancing physicochemical and pharmacological properties. [J]. International journal of pharmaceutics, 2024, 653123857-653123865.

[3] Raza H, Abrar A, Ashraf A, et al. Design, Synthesis, Evaluation, and Molecular Docking Study of Ascorbic Acid Dual-Coated Omeprazole Pellets and the Antioxidative Effect of Ascorbic Acid on Omeprazole-Induced Renal Injury in an Animal Model. [J]. ACS omega, 2024, 9(1):1143-1155.

[4] Adam M. Severe hyponatraemia peripartum associated with omeprazole therapy [J]. Obstetric Medicine, 2023, 16(4): 245-246.

[5] Estrada R A C,Sánchez E,Córdova F A M, et al. Photosynthetic Efficiency in Green Bean Plants through the Application of Omeprazole and Melatonin at Low Doses [J]. International Journal of Plant Biology, 2023, 14(4): 864-878.

[6] Habib M,Amin N,Saeed A, et al. Is the Addition of Sublingual Melatonin to Omeprazole Superior to Omeprazole Alone in the Management of Gastroesophageal Reflux Disease Symptoms: A Clinical Trial. [J]. The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology, 2023, 34(12):1206-1211.

[7] Juyoung S, Seulgi B. In vitro effects of omeprazole in combination with antifungal compounds against Malassezia pachydermatis. [J]. Veterinary medicine and science, 2023, 9(6):2594-2599.

[8] Savaş K,Hassane L,Abhinay T, et al. Molecular insights into the corrosion inhibition mechanism of omeprazole and tinidazole: a theoretical investigation [J]. Molecular Simulation, 2023, 49(17):1632-1646.